Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forxiga versus placebo for inflammatory and heart failure biomarkers in adults with type 2 diabetes and atherosclerotic coronary disease
MOH_2017-12-04_001994Phase 4Not yet recruiting
- Sponsor
- פרופסור רוברט קלמפפנר
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), atherosclerotic disease and coronary arteriosclerosis (2 arms), sponsored by פרופסור רוברט קלמפפנר. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on MOH_2017-12-04_001994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-04_001994.